My current research focuses on the clinical application of Antibody-Drug Conjugates (ADCs) in cancer treatment. My goal is to help optimise the clinical use of ADCs, thereby enhancing therapeutic efficacy and minimising adverse reactions. Furthermore, I aspire to engineer next-generation ADCs that offer superior potency and an improved safety profile.